Cargando…

The New T Cell Subset Opens a New Realm for Tumor Immunotherapy

Immunotherapy with immune checkpoint inhibitors had achieved great success. However, only a subset of patients responds positively to these therapies. The latest study published on Nature by Chou and colleagues found a new T cell subset from tumor-infiltrating T cells which lack PD-1 on the cell sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Huanjin, Zeng, Chong, Wang, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666835/
https://www.ncbi.nlm.nih.gov/pubmed/36377088
http://dx.doi.org/10.1177/09636897221138037
Descripción
Sumario:Immunotherapy with immune checkpoint inhibitors had achieved great success. However, only a subset of patients responds positively to these therapies. The latest study published on Nature by Chou and colleagues found a new T cell subset from tumor-infiltrating T cells which lack PD-1 on the cell surface and potent cytotoxic activities against tumor cells. This finding provides a novel insight into the development of new therapies for tumors that do not respond to immune checkpoint blockade in the future.